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for designing CER studies projects. The expert working group ranked technologies 
according to suitability for both CED and the guideline projects. The top 3 technolo-
gies that emerged for CED were 1) pharmacogenetic guidance of warfarin dosing; 
2) catheter ablation for atrial ﬁbrillation; and 3) percutaneous aortic valve replace-
ment. For the guidelines, the ranking was 1) C-reactive protein tests; 2) genetic 
testing for heart disease; and 3) bioabsorbable stents. CONCLUSIONS: A prospec-
tively developed multi-step process focusing on technologies within a disease area 
may improve the process of prioritizing technologies for CER, offering more direct 
guidance to researchers and policy makers. Notably, CMTP is initiating a CED 
project and the advisory workgroup selected the warfarin dosing topic, indicating 
the success of the process in choosing a relevant technology.
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OBJECTIVES: To analyze the difference of in-stay hospitalization frequency between 
Congestive Heart Failure (CHF) patients who are on the recommended medication 
and those who are not. METHODS: We use the inpatient, outpatient and medication 
ﬁles from the Thomson Reuters MarketScan data records of 2000 and 2001. First, 
we extract patients with CHF from the inpatient and outpatient ﬁles using ICD9 codes. 
Next, we extract these patients from the medication ﬁles. Depending on the NYHA 
classiﬁcation, there is a recommended combination of medication a CHF patient 
should have. We use these medications to divide the patients into two groups. Then, 
we analyze the data using logistic regression, kernel density estimation and ANOVA. 
The preprocessing and the statistical analysis are done using SAS software. RESULTS: 
The analysis yields a statistically noteworthy difference in proportions of number of 
in- stay hospitalizations between people on the recommended treatment and those 
who are not. Also, there is signiﬁcant difference in length of stay for the two groups. 
CONCLUSIONS: Being on the recommended combination of medication has a sig-
niﬁcant impact on the health care outcome for CHF patients.
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OBJECTIVES: To examine the effect of an employer-sponsored, pharmacist-provided 
medication therapy management program (MTM) on clinical outcomes and process 
measures in patients with diabetes and hypertension METHODS: A prospective, 
intent-to-treat, pre-post longitudinal study. Patients were Lucas County employees and 
dependents with diabetes, hypertension, or both. The MTM services were provided 
by independent pharmacists in Northwest Ohio at seven sites. ADA and JNC-VII 
guidelines were used to design interventions and set patient goals. Data was analyzed 
using SPSS v17.0 for three groups—hypertension only, diabetics, and hypertensive 
diabetics. Wilcoxon signed-rank test was used to compare 2 time points and the 
Friedman test was used to compare readings at baseline, 6,12,and 18 months. 
RESULTS: Five hundred eighty six patients enrolled at baseline. The Hypertension 
only group mean systolic blood pressure (SBP) improved from 135.37 ± 18.85 to 
130.33 ± 18.35 (p = 0.057). Diastolic blood pressure (DBP) improved from 81.71 ± 
10.70 to 80.35 ± 11.12 (p = .386). Uncontrolled hypertensive patient’s SBP mean 
improved from 153.03 ± 12.37 to 138.91 ± 19.74 (p < 0.01). DBP improved from 
97.07 ± 5.71 to 85.6 ± 13.20 (p < 0.05). For hypertensive diabetic patients SBP 
improved from 134.59 ± 18.99 to 128.35 ± 18.55 (p = 0.20). DBP improved from 
81.52 ± 11.25 to 79.52 ± 12.08 (p = 0.75). Uncontrolled diabetic hypertensive patients 
SBP mean improved from 145.96 ± 13.83 to 135.29 ± 17.62 (p < 0.05). DBP improved 
from 87.51 ± 6.54 to 82.71 ± 11.92 (p = 0.439). For uncontrolled diabetic patients 
A1c improved signiﬁcantly from 8.02 ± 1.31 to 7.41 ± 0.99 (p < 0.001). Patients with 
controlled A1c at baseline were able to maintain control for the 18 months of partici-
pation in the study. Upon being advised by their pharmacists more patients visited 
their dentist, podiatrist, and ophthalmologist. CONCLUSIONS: Pharmacists were 
able to help patients maintain A1c and BP goals thereby preventing future complica-
tions and costs to the employer.
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OBJECTIVES: ACEI or ARB therapy in patients with diabetes has been shown to 
delay progression to renal failure. This study evaluated the impact of a mailing inter-
vention to health care providers aimed at optimizing ACEI or ARB therapy in patients 
with diabetes plus hypertension and/or nephropathy. METHODS: A retrospective 
cohort study was performed using pharmacy claims data from a large Medicare Part 
D plan to evaluate an intervention notifying providers of missing ACEI/ARB therapy 
for 28,348 patients with diabetes plus hypertension and/or nephropathy not qualifying 
for Medication Therapy Management services (Non-MTM). A control cohort of 
50,757 Non-MTM Medicare Part D patients with diabetes plus hypertension and/or 
nephropathy not receiving ACEI or ARB therapy during the 7-month identiﬁcation 
period was selected from an earlier timeframe to be compared to the intervention 
cohort. The primary outcome was the percentage of identiﬁed patients initiating ACEI 
or ARB therapy during the 4-month post-intervention period. Logistic regression was 
performed using a dependent variable of initiation vs. no initiation of ACEI or ARB 
therapy in the post-intervention period. Independent variables included age, gender, 
chronic disease score, and hypertension and nephropathy diagnoses. RESULTS: 
During the post-intervention period, the unadjusted proportion of those beginning 
ACEI or ARB therapy was 15.0% for the intervention group compared to 12.2% for 
the control group (p < 0.0001). After adjusting for baseline characteristics, intervened 
patients had greater odds of initiating ACEI or ARB therapy compared to control 
patients (OR 1.40; 95% CI 1.33–1.48). A limitation of the evaluation is that the 
identiﬁcation and measurement periods for the control group were in a different part 
of the year than the intervention cohort. CONCLUSIONS: Intervention in patients 
with diabetes plus hypertension and/or nephropathy via health care providers demon-
strated an increased likelihood of initiation of ACEI or ARB therapy compared to a 
control group.
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OBJECTIVES: In addition to elevated low-density lipoprotein cholesterol (LDL-C), 
studies have implicated decreased high-density lipoprotein cholesterol (HDL-C) and 
elevated triglycerides (TG) as independent modiﬁable risk factors for cardiovascular 
disease. This study determined the proportion of patients with a single lipid abnormal-
ity (SLA) versus mixed dyslipidemia and their respective treatments among a large 
sample of managed care patients. METHODS: A retrospective cohort study of adults 
with a complete lipid panel between 1/1/2005 and 12/31/2008 in a US national health 
plan with >10 million commercial and Medicare Advantage members was conducted. 
SLA was deﬁned as one of the following: high LDL-C based on NCEP ATP III guide-
lines, low HDL-C (<40 mg/dL), or high TG (≥200 mg/dL). Mixed dyslipidemia was 
deﬁned as having ≥2 of the lipid abnormalities. Proportion of patients with an SLA 
or mixed dyslipidemia and lipid-modifying therapy patterns were evaluated. 
RESULTS: A total of 247,322 patients had dyslipidemia in the 4-year observation 
period; 68% had an SLA and 32% had mixed dyslipidemia. Of patients with SLA, 
47% had elevated LDL-C, 32% had low HDL-C, and 21% had elevated TG. For 
patients with an SLA, only 29% received lipid-modifying therapy, with 71% of those 
receiving statin monotherapy. Of patients with mixed dyslipidemia, 42% had low 
HDL-C and high TG, 22% had high LDL-C and low HDL-C, 21% had high LDL-C 
and high TG, and 15% had all 3 abnormal lipid parameters. In the mixed dyslipidemia 
group, only 33% received lipid-modifying therapy, with 58% of those receiving statin 
monotherapy and 19% receiving multi-pill combination therapy. CONCLUSIONS: 
The lack of treatment and inadequate treatment observed in this real-world study 
indicates an unmet medical need in managing lipid levels among dyslipidemic patients, 
including patients with mixed dyslipidemia.
PCV141
UTILIZATIONAND EXPENDITURE TRENDS FOR BOTH ANGIOTENSIN-
CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR 
BLOCKERS IN THE MEDICAID PROGRAM
Bian B1, Guo JJ2, Kelton C2, Wigle P1
1Univeristy of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: Both angiotensin-converting-enzyme inhibitors (ACEIs) and angioten-
sin receptor blockers (ARBs) have been widely used for treatment of hypertension, 
heart failure, diabetes mellitus and kidney disease. The purposes of this study were to 
describe the utilization, price and expenditure trends of ACEIs and ARBs and to assess 
market-share competition between ACEIs and ARBs. METHODS: A retrospective, 
descriptive time-series analysis was performed using the National Medicaid pharmacy 
claims database from 1991 to 2008. The quarterly prescription numbers and reim-
bursement amounts were calculated over time by summing data for individual drug 
products. The quarterly per-prescription reimbursement as a proxy for drug price was 
computed for all brands and generics of ACEIs and ARBs. The market shares were 
calculated based on both prescription numbers and Medicaid payments. RESULTS: 
The ACEI prescriptions increased from 4.8 million in 1991 to 16.5 million in 2004, 
then dropped to 2.3 million in 2008. Meanwhile, ARB prescriptions increased from 
0.03 million in 1995 to 7.5 million in 2004, then dropped to 2.1 million in 2008. 
Concurrently, annual expenditure for ACEIs increased from $179 million in 1991 to 
$593 million in 2002, and dropped to $64 million in 2008. Expenditure for ARBs 
increased from $1.3 million in 1995 to $515 million in 2005, and dropped to $174 
million in 2008. Market shares for generic ACEIs like captopril, lisinopril and enala-
pril increased rapidly. All brand-name prices for ARBs and ACEIs increased over time 
regardless of new branded or generic drug entry, while generic prices decreased over 
time. CONCLUSIONS: Dramatically increased utilization of both ACEIs and ARBs 
may be due to their wide therapeutic indications and efﬁcacy. A signiﬁcant drop in 
utilization from 2006–2008 was related to the introduction of Medicare Part D. 
Increased utilization of generic ACEIs was likely due to the Medicaid generic substitu-
tion policy and changes in prescribing patterns.
